Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.826 – $0.947
Volume 37,990
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$589.67K
Price / earnings
—
Price / book
0.13×
Price / sales
1.1×
EV / sales
-14.16×
EV / EBITDA
0.45×

Profitability

Earnings per share
-$25.28
Return on assets
-188.37%
Return on equity
-364.33%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.97×
Quick ratio
1.97×
Cash ratio
1.92×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.96M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DCOY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$307.43K$227.63K$0
Cost of revenue$0$0$0
Gross profit$307.43K$227.63K$0
Selling, general and administrative$1.75M$1.33M$1.53M
Research and development$1.57M$1.3M$749.81K
Total operating expenses$3.32M$2.63M$2.28M
Operating income-$3.01M-$2.4M-$2.28M
Interest expense$0$0$0
Income before taxes-$2.99M-$2.37M-$2.22M
Income taxes$0$0$0
Net income-$2.99M-$2.37M-$2.22M
Net income attributable to common shareholders-$2.99M-$2.37M-$2.22M
EBITDA-$2.99M-$2.39M-$2.28M
Basic earnings per share-$3.53-$4.46-$4.18
Diluted earnings per share-$3.53-$4.46-$4.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 9, 20261-for-12reverse split